Apellis Pharmace SEC Filings

Apellis Pharmaceuticals ownership filing: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 249,635 shares of Apellis common stock, representing 0.20% of the class as of 03/31/2026. The filing states shared voting power of 239,469 and shared dispositive power of 249,635.

BIOGEN INC. filed an initial ownership report for its relationship with Apellis Pharmaceuticals, Inc. under a Tender and Support Agreement dated March 31, 2026. The agreement covers common stock held by several existing Apellis holders and may form a “group” that beneficially owns in aggregate more than 10% of the outstanding common stock for Section 13(d) purposes.

However, the agreement does not give Biogen any pecuniary interest in the Apellis common stock, related RSUs, or options, so Biogen is not considered a beneficial owner for Section 16 reporting. The Form 3 shows zero indirect holdings of common stock and stock options following the reporting date.

Biogen Inc. has filed a Schedule 13D reporting beneficial ownership of 18,469,475 shares of Apellis Pharmaceuticals common stock, representing 14.2% of the class as of March 31, 2026, due to a tender and support agreement with key Apellis stockholders.

Biogen, through wholly owned subsidiary Aspen Purchaser Sub, Inc., agreed to launch a tender offer to acquire all outstanding Apellis shares for $41.00 in cash per share plus one non-transferable contingent value right (CVR) per share. Each CVR may pay up to an additional $4.00 in cash if specified net sales milestones for SYFOVRE and related products of at least $1.5 billion or $2.0 billion in certain years from 2027 to 2031 are achieved.

The offer will be open for 20 business days, followed by a merger under Section 251(h) of Delaware law that will make Apellis a wholly owned Biogen subsidiary and lead to delisting of Apellis common stock. Biogen plans to finance the merger with cash on hand and term loan proceeds.

Biogen’s subsidiary announced pre-commencement communications about a planned tender offer to acquire all outstanding shares of Apellis Pharmaceuticals under an Agreement and Plan of Merger dated March 31, 2026. The communication states the tender offer has not yet commenced and that formal offer materials will be filed on Schedule TO when the offer begins. It directs Apellis securityholders to read the forthcoming offer documents and the solicitation/recommendation statement on Schedule 14D-9 carefully and to obtain those materials from the SEC or company websites. The filing includes customary forward-looking disclaimers and identifies social media posts made on March 31, 2026 as an exhibit.

Apellis Pharmaceuticals agreed to be acquired by Biogen through a cash tender offer and follow‑on merger. Biogen will offer Apellis stockholders $41.00 in cash per share plus a non‑transferable contingent value right (CVR) that can pay up to an additional $4.00 per share in cash if specified SYFOVRE® annual global net sales milestones are met. The implied upfront transaction value is approximately $5.6 billion. A tender offer will run for 20 business days, subject to customary conditions including a majority tender, antitrust clearance under the HSR Act and other standard closing conditions. Apellis’ board unanimously approved the deal and recommends stockholders tender their shares. Certain directors, executives and a major stockholder holding about 14% of Apellis shares signed a tender and support agreement to back the transaction.

Apellis Pharmaceuticals Schedule 13G/A amendment filed by The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report separately in reliance on SEC Release No. 34-39538.

The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Apellis Pharmaceuticals Chief Executive Officer Cedric Francois reported gift transfers of common stock. On March 11, 2026, entities associated with him made bona fide gifts totaling 129,738 shares, including a transfer of 64,869 shares to The Cedric Francois Irrevocable Trust of 2023 - 2.

After these gifts, he directly holds 425,968 shares. The filing also lists indirect holdings through several trusts, including 372,815 shares in The Cedric Francois Irrevocable Trust of 2023 - 2, 472,065 shares in The Cedric Francois Irrevocable Trust of 2023, 300,000 shares in The Francois Grossi Trust, and 234,411 shares in The Francois-DuBois Educational Trust.

Apellis Pharmaceuticals director Mikael Dolsten reported receiving new equity awards. On February 27, 2026, he was granted stock options for 24,135 shares at an exercise price of $20.96 per share, vesting in equal one-third installments annually over three years, subject to continued service.

He also received 14,312 shares of common stock as a restricted stock unit grant. This restricted stock unit will fully vest on the first anniversary of the grant date, or upon a later termination of his service as a director at his election, provided he continues serving as a director.

Apellis Pharmaceuticals, Inc. director Mikael Dolsten filed an initial statement of beneficial ownership on Form 3. This filing establishes him as an insider for reporting purposes, but it does not list any specific stock transactions or changes in his holdings.